Previous 10 | Next 10 |
home / stock / redif / redif news
RedHill Biopharma to Present at SVB Leerink Global Healthcare and BIO CEO & Investor Conferences RedHill Biopharma to Present at SVB Leerink Global Healthcare and BIO CEO & Investor Conferences PR Newswire TEL AVIV, Israel and RALEIGH, N.C. , Feb. 9...
RedHill Biopharma Announces Positive DSMB Futility Review for Phase 2/3 COVID-19 Study of Opaganib Following interim review of unblinded safety and efficacy data, independent DSMB unanimously recommends continuation of the global Phase 2/3 study of orally-administered opaganib f...
RedHill Biopharma Further Expands Opaganib Manufacturing Capacity for COVID-19 with Cosmo Pharmaceuticals New agreement further expands manufacturing capacity for orally-administered opaganib following positive top-line data from its Phase 2 COVID-19 study, progress with the ong...
RedHill Biopharma Announces Closing of $25 Million Bought Deal Offering PR Newswire TEL AVIV, Israel and RALEIGH, N.C. , Jan. 14, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical compan...
RedHill Biopharma Increases Previously Announced Bought Deal to $25 Million PR Newswire TEL AVIV, Israel and RALEIGH, N.C. , Jan. 12, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical co...
RedHill Biopharma Announces $10 Million Bought Deal Offering PR Newswire TEL AVIV, Israel and RALEIGH, N.C. , Jan. 11, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today an...
RedHill Biopharma's RHB-204 Granted FDA Fast Track Designation for NTM Disease U.S. Phase 3 study underway to evaluate RHB-204 as a first-line, stand-alone, oral treatment for pulmonary NTM disease - a rare condition with no FDA-approved first-line therapy FDA Fast Track des...
RedHill Biopharma Announces Positive Top-Line Safety and Efficacy Data from Phase 2 COVID-19 Study of Opaganib Preliminary data from the non-powered U.S. Phase 2 study of 40 hospitalized patients shows that orally-administered opaganib was safe, with no material safety differenc...
RedHill Biopharma Extends Talicia® Unrestricted National and Regional Commercial Coverage to Over 40 Million Additional Americans TEL AVIV, Israel and RALEIGH, N.C. , Dec. 7, 2020 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Compa...
RedHill Biopharma Expands U.S.-Based Manufacturing Capacity of Opaganib for COVID-19 RedHill adds two more manufacturing partners, both U.S.-based, for large-scale manufacturing of opaganib, in preparation for potential emergency use applications as early as Q1/2021 The new ...
News, Short Squeeze, Breakout and More Instantly...
Redhill Biopharma Ltd Ord Company Name:
REDIF Stock Symbol:
OTCMKTS Market:
Redhill Biopharma Ltd Ord Website:
RedHill Biopharma Reports Operational Highlights and Third Quarter 2021 Financial Results Canada NewsWire RedHill Accelerates its Two Advanced COVID-19 Pill Clinical Programs in Light of their Potential Against Omicron Acting independently of spike protein mutation...
RedHill Biopharma Announces Closing of $15.5 Million Public Offering of American Depositary Shares PR Newswire TEL AVIV, Israel and RALEIGH, N.C. , Nov. 23, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty b...
RedHill Biopharma Announces Last Patient Randomized in Part A of Ongoing Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized Patients Canada NewsWire - Recruitment completed for Part A of the Phase 2/3 study of once-daily orally-administered RHB-107...